Pacgen Biopharmaceuticals Names Dr. Alan Moore and Mr. Kevin McGarry to the Board of Directors

Vancouver, BC, Canada, July 17, 2006 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that at its recent Annual General Meeting, Dr. Alan Moore and Mr. Kevin McGarry have been added to its Board of Directors.

Dr. Moore brings to Pacgen over 27 years of extensive drug development and clinical expertise. Dr. Moore accumulated 23 years of management experience in pharmaceutical research at Procter & Gamble where he held several senior positions including General Manager of Cardiac Research and Development. Dr. Moore was the Executive VP of clinical development and regulatory affairs at Cardiome Pharma Corp. from 2002 to 2004 and currently serves as the Chief Clinical and Regulatory Officer at Stem Cell Therapeutics. Dr. Moore received his Ph.D. in pharmacology from the University of Aston in Birmingham, England.

During his esteemed career he has completed 11 investigational new drug (“IND”) applications or supplemental IND’s, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications. In addition to being named to the Board of Directors, Dr. Moore has also been appointed as the Chair of Pacgen’s Clinical Advisory Board. “The addition of Dr. Alan Moore to these boards is a significant one given his wealth of experience and impressive track record” said Dr. David Cheng, President and CEO of Pacgen. “Dr. Moore will provide invaluable leadership to augment our clinical development and regulatory programs” added Dr.Cheng.

Mr. McGarry, B.Sc., MBA, is currently the Chief Executive Officer of Lombard Life Sciences (“Lombard”) which manages the Western Life Sciences Venture Fund L.P (“Western Life Sciences”). Western Life Sciences manages a CDN $45 million fund and has a mandate to create, acquire, and develop early and later stage human bio/medical technology companies. Previous to Lombard, Mr. McGarry was the founding partner and Chief Executive Officer of Keystone Technologies Inc. (“Keystone”), an early-stage biotechnology venture fund. As CEO of Keystone, Mr. McGarry successfully capitalized and structured four biotechnology companies. “Mr. McGarry brings to Pacgen an extensive business and financial background, and a wealth of biotechnology experience” said Dr. Cheng.

“We are delighted to have both Dr. Moore and Mr. McGarry joining us” said Dr. Cheng. “These additions demonstrate our commitment to building a Board with track records and expertise to oversee our strategic direction and development as Pacgen continues to grow” Dr. Cheng added. Pacgen’s Board of Directors now consists of Mr. Chung-Yu Wang, EMBA, Dr. Hassan Salari, Ph.D., Mr. Michael Evans, MBA, CFA, CBV, Dr. Telvin Ju, Ph.D., Dr. Alan Moore, Ph.D., Mr. Kevin McGarry, MBA., and Dr. David Cheng, Ph.D.

About Pacgen

Pacgen Biopharmaceuticals Corporation is an international life sciences company specializing in the development of innovative peptide therapeutics for the prevention and treatment of infectious diseases and immune system regulations where current therapies are inadequate or ineffective. Pacgen’s current clinical programs include drug candidates for the treatment of oral candidiasis in HIV-infected patients (phase I/II), prevention and treatment of acute respiratory distress syndrome (preclinical), prevention of ventilator-associated pneumonia (preclinical), and treatment of chronic Hepatitis B & C infections (research & development).

Pacgen is headquartered in Vancouver, British Columbia, Canada. For additional information, please visit www.pacgenbiopharm.com.

Contact
James Beesley, B.Sc., D.C.
Director of Corporate Communication
Pacgen Biopharmaceuticals Corporation
Tel: (604) 436-4388 Ext. 107
Email: james@pacgenbiopharm.com

PDF: 
PDF icon news_release20060717.pdf